FDA, Penn get personal
This article was originally published in The Tan Sheet
Executive SummaryFollowing FDA's Sept. 12 health information advisory regarding melamine-contaminated infant formula from China, the agency says Sept. 23 "there is no known threat of contamination in infant formula manufactured by companies that have met the requirements to sell such products in the United States." While state and local officials collaborating with the agency have not found Chinese formula on store shelves in large Asian enclaves in the U.S., FDA says it is taking "proactive measures" to sample and test other imported milk-derived ingredients and finished food products for Chinese milk proteins (2"The Tan Sheet" Sept. 15, 2008, In Brief)
You may also be interested in...
The $9.7bn acquisition hinges on the small interfering RNA inclisiran, but an ongoing cardiovascular outcomes trial, manufacturing hurdles, and reimbursement challenges provide subjects for concern.
US congressional leaders and medtech industry advocacy group AdvaMed are giving their full-throated endorsement to a US-Mexico-Canada (USMCA) trade agreement announced by the US Trade Representative's Office on 10 December. See what AdvaMed's president and CEO, Scott Whitaker, said about it in a statement here.